TMDX TransMedics Group, Inc. logo

TMDX TransMedics Group, Inc.

Healthcare
$68.94+0.12%ClosedMarket Cap: $2.38B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

19.35

PEG

0.04

P/B

4.80

P/S

3.75

EV/EBITDA

19.94

DCF Value

$-1,150.76

FCF Yield

6.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

59.1%

Operating Margin

14.9%

Net Margin

27.0%

ROE

41.9%

ROA

12.0%

ROIC

6.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$173.9M$7.3M$
Q4 null$160.8M$105.4M$
FY null$605.5M$190.3M$
Q3 null$143.8M$24.3M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$124.33

Target (Median)

$129.50

Target Range

$85.00 - $142.00

2 Strong Buy7 Buy3 Hold0 Sell0 Strong Sell
TD CowenBuy
2026-05-06
NeedhamBuy
2026-05-06
Canaccord GenuityBuy
2026-05-06
StifelHold
2026-05-06
Piper SandlerOverweight
2026-05-06

Trading Activity

Insider Trades

View All
Weill Daviddirector
SellFri May 22
TOBIN JAMES Rdirector
SellFri May 22
RAINES MERILEEdirector
SellFri May 22
Lovell Stephaniedirector
SellFri May 22
Kania Edwindirector
SellFri May 22

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

2.06

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Peers